Bogachev V Iu, Boldin B V, Turkin P Iu
Department of Faculty Surgery No 2, Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia.
Angiol Sosud Khir. 2018;24(1):102-106.
Presented herein are the results of the observational follow up study programme dedicated to the assessment of appropriate use of adjuvant therapy with Detralex while carrying out phlebosclerosing treatment in patients suffering from dilated intradermal veins (clinical class C1 according to the CEAP classification). A conclusion was drawn that administration of Detralex for 60 days decreased the incidence rate of typical undesirable side events after phlebosclerosing therapy, thus making the use of this drug appropriate in routine clinical practice.
本文介绍了一项观察性随访研究计划的结果，该计划旨在评估在对患有扩张性真皮内静脉（根据CEAP分类为临床C1级）的患者进行静脉硬化治疗时辅助使用Detralex的合理性。得出的结论是，Detralex给药60天可降低静脉硬化治疗后典型不良副作用的发生率，因此该药物在常规临床实践中的使用是合理的。
